In 1998, the startup company Illumina launched a revolution in the life sciences industry by developing technology to slash the costs of identifying and mapping genetic material. Now, a little over 20
The up to $818 million deal between Locus Biosciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) that was announced yesterday points toward a new path for CRISPR gene editing te
Paul Dabrowski, the chief executive officer of Synthego, which provides genetically engineered cells to scientists and researchers, worries about a future where access to the genetic technologies that
Synthego, a provider of gene editing services for genomics research and experimentation, has launched a new suite of products that give researchers access to edited genetic material to make experiment
8VC, the early-stage, San Francisco-based venture firm founded in 2015 by serial entrepreneur Joe Lonsdale and four other general partners, has closed it second early-stage venture fund with $640 mill
We hear a lot about the potential and implications of the gene-editing technique CRISPR, but it's not like just anyone can open up an app, pick a gene they don't like, and build the molecular machiner
Genetic engineering startup Synthego makes synthetic ribonucleic acid (RNA), an important genetic component found in all living cells and also used in CRISPR Cas9, a technology enabling scientists to
When an entrepreneur quits their job to found a company, you're bound to hear the words "I want to build something meaningful. I want to have a bigger impact." Well, if your job is building rockets fo